• New Leaf Venture Partners Closes $450 Million Healthcare Fund
  

• CoNCERT Pharmaceuticals Raises $37 Million in Series C Financing
  

• Stromedix Raises $25 Million Series B for Fibrosis Programs, Begins Clinical Trial
  

• Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
  
  

New Leaf Venture Partners is a leader in healthcare technology venture investing. Our investment professionals bring a unique blend of technological, clinical, and operational experience to our investments. We work closely with our entrepreneurs to help build successful portfolio companies. We focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

New Leaf currently manages $1.3 billion in assets. This includes our newest fund, New Leaf Ventures II, L.P. which closed with commitments of $450 million in October 2007, New Leaf Ventures I, L.P. and the healthcare technology portfolio of the Sprout Group, one of the oldest U.S. venture capital fund groups.